Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2 - PubMed (original) (raw)
. 2004 Aug;25(8):1517-24.
doi: 10.1093/carcin/bgh150. Epub 2004 Mar 19.
Affiliations
- PMID: 15033900
- DOI: 10.1093/carcin/bgh150
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2
Amy M Meyer et al. Carcinogenesis. 2004 Aug.
Abstract
Epidemiological investigations suggest that chronic lung inflammation increases lung cancer risk. Pharmacologic and genetic evidence in mouse models indicates that lipid mediators released during pulmonary inflammation enhance lung tumor formation. Cytosolic phospholipase A2 (cPLA2) catalyzes arachidonic acid (AA) release from membrane phospholipids. AA can then lead to the synthesis of several classes of lipid mediators, including prostaglandin (PG) biosynthesis through the cyclooxygenase (COX) pathway. We investigated a role for cPLA2 in mouse lung tumorigenesis by using mice genetically deficient in cPLA2. After multiple urethane injections into cPLA2 null mice and wild-type littermates, the number of lung tumors was determined. cPLA2 null mice developed 43% fewer tumors (from 16 +/- 2 to 9 +/- 2 tumors/mouse; P < 0.05) than wild-type littermates. cPLA2, COX-1, COX-2 and microsomal prostaglandin E2 synthase (mPGES), examined by immunohistochemistry, are present in alveolar and bronchiolar epithelia and in alveolar macrophages in lungs from naive mice and tumor-bearing mice. Tumors express higher levels of each of these four enzymes than control lungs, as determined by immunoblotting. No differences were detected in the contents of COX-1, COX-2 and mPGES between wild-type and cPLA2 null mice. Although the steady-state levels of prostaglandin E2 and prostaglandin I2 in lung tissue extracts prepared from wild-type or cPLA2 (-/-) mice were not significantly different, both prostaglandins markedly increased in tumors from wild-type mice, an increase that was significantly blunted in tumors from cPLA2 (-/-) mice. These results demonstrate a role for cPLA2 in mouse lung tumorigenesis that may be mediated by decreased prostaglandin synthesis.
Similar articles
- Role of cytosolic phospholipase A(2) in prostaglandin E(2) production by lung fibroblasts.
Ghosh M, Stewart A, Tucker DE, Bonventre JV, Murphy RC, Leslie CC. Ghosh M, et al. Am J Respir Cell Mol Biol. 2004 Jan;30(1):91-100. doi: 10.1165/rcmb.2003-0005OC. Epub 2003 Jul 3. Am J Respir Cell Mol Biol. 2004. PMID: 12842849 - Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2.
Murakami M, Kuwata H, Amakasu Y, Shimbara S, Nakatani Y, Atsumi G, Kudo I. Murakami M, et al. J Biol Chem. 1997 Aug 8;272(32):19891-7. doi: 10.1074/jbc.272.32.19891. J Biol Chem. 1997. PMID: 9242654 - The expression of brain cyclooxygenase-2 is down-regulated in the cytosolic phospholipase A2 knockout mouse.
Bosetti F, Weerasinghe GR. Bosetti F, et al. J Neurochem. 2003 Dec;87(6):1471-7. doi: 10.1046/j.1471-4159.2003.02118.x. J Neurochem. 2003. PMID: 14713302 - Prostaglandins and other lipid mediators in Alzheimer's disease.
Bazan NG, Colangelo V, Lukiw WJ. Bazan NG, et al. Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:197-210. doi: 10.1016/s0090-6980(02)00031-x. Prostaglandins Other Lipid Mediat. 2002. PMID: 12432919 Review. - Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids.
Goppelt-Struebe M. Goppelt-Struebe M. Biochem Pharmacol. 1997 May 15;53(10):1389-95. doi: 10.1016/s0006-2952(97)00018-x. Biochem Pharmacol. 1997. PMID: 9260864 Review.
Cited by
- Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.
Zhang X, Wu Q, Gan L, Yu GZ, Wang R, Wang ZS, Wang JJ, Wang X. Zhang X, et al. Med Oncol. 2013 Mar;30(1):454. doi: 10.1007/s12032-012-0454-y. Epub 2013 Jan 10. Med Oncol. 2013. PMID: 23307260 - Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.
Haynes A, Shaik MS, Chatterjee A, Singh M. Haynes A, et al. Pharm Res. 2005 Mar;22(3):427-39. doi: 10.1007/s11095-004-1881-z. Pharm Res. 2005. PMID: 15835749 - Regulation of inflammation in cancer by eicosanoids.
Greene ER, Huang S, Serhan CN, Panigrahy D. Greene ER, et al. Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):27-36. doi: 10.1016/j.prostaglandins.2011.08.004. Epub 2011 Aug 16. Prostaglandins Other Lipid Mediat. 2011. PMID: 21864702 Free PMC article. Review. - Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Kupert E, Anderson M, Liu Y, Succop P, Levin L, Wang J, Wikenheiser-brokamp K, Chen P, Pinney SM, Macdonald T, Dong Z, Starnes S, Lu S. Kupert E, et al. BMC Cancer. 2011 Dec 9;11:513. doi: 10.1186/1471-2407-11-513. BMC Cancer. 2011. PMID: 22151235 Free PMC article. - Roles of cPLA2alpha and arachidonic acid in cancer.
Nakanishi M, Rosenberg DW. Nakanishi M, et al. Biochim Biophys Acta. 2006 Nov;1761(11):1335-43. doi: 10.1016/j.bbalip.2006.09.005. Epub 2006 Sep 15. Biochim Biophys Acta. 2006. PMID: 17052951 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials